奋卡巴米 | 3735-90-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 奋卡巴米
• 中文别名: 芬卡米特；二苯硫酰胺
• 英文名称: diphenyl-carbamothioic acid, S-[2-(diethylamino)ethyl] ester
• 英文别名: phencarbamide；fencarbamide；S-[2-(diethylamino)ethyl] N,N-diphenylcarbamothioate
• CAS: 3735-90-8
• 化学式: C₁₉H₂₄N₂OS
• 分子量: 328.478
• InChiKey: BZGIPVGCJGXQTA-UHFFFAOYSA-N

物化性质

• 熔点：
  48-49°
• 沸点：
  bp0.01 120-126°
• 密度：
  1.0897 (rough estimate)

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  23
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  48.8
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2930909090

文献信息

• [EN] 4-SUBSTITUTED BENZIMIDAZOLES AND THEIR USE AS INHIBITORS OF GASTRIC SECRETION<br/>[FR] BENZIMIDAZOLES SUBSTITUES EN POSITION 4 ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE LA SECRETION GASTRIQUE
  申请人：ALTANA PHARMA AG

  公开号：WO2004054984A1

  公开（公告）日：2004-07-01

  The invention relates to 6-substituted benzimidazoles of formula 1, in which X is O (oxygen) or NH and Y has either the meaning -CH2-Ar wherein Ar is a mono- or bicyclic aromatic residue, or Y denotes the group gp, formula (gp) wherein Z has the meaning -CHR8- or -CHR8-CHR9-. The compounds have gastric secretion inhibiting and excellent gastric and intestinal protective action properties.

  这项发明涉及式1中的6-取代苯并咪唑，其中X为O（氧）或NH，Y具有以下含义之一：-CH2-Ar，其中Ar是单环或双环芳香基团；或Y表示群gp，式（gp），其中Z具有含义-CHR8-或-CHR8-CHR9-。这些化合物具有抑制胃酸分泌和优异的胃肠保护作用特性。
• [EN] DIFLUORO-SUBSTITUTED IMIDAZOPYRIDINES<br/>[FR] IMIDAZOPYRIDINES DIFLUORO-SUBSTITUEES
  申请人：ALTANA PHARMA AG

  公开号：WO2006040338A1

  公开（公告）日：2006-04-20

  The invention provides compounds of the formula (1), in which the substituents and symbols are as defined in the description. The compounds inhibit the secretion of gastric acid.

  该发明提供了式（1）的化合物，其中取代基和符号如描述中所定义。这些化合物抑制胃酸的分泌。
• [EN] CYCLIC BENZIMIDAZOLES<br/>[FR] BENZIMIDAZOLES CYCLIQUES
  申请人：ALTANA PHARMA AG

  公开号：WO2004087701A1

  公开（公告）日：2004-10-14

  The invention relates to cyclic benzimidazoles of formula (1), (1) in which the substituents and symbols have the meanings indicated in the description. The compounds have gastric secretion inhibiting and excellent gastric and intestinal protective action properties.

  该发明涉及公式（1）中的环状苯并咪唑，其中取代基和符号具有描述中所示的含义。这些化合物具有抑制胃酸分泌和优异的胃肠保护作用特性。
• Hydroxylated nebivolol metabolites
  申请人：O'Donnell P. John

  公开号：US20070014733A1

  公开（公告）日：2007-01-18

  Hydroxylated nebivolol metabolites increase NO release from human endothelial cell preparations in a concentration dependent fashion following acute administration. In addition, hydroxylated nebivolol metabolites, including but not limited to 4-hydroxy-6,6′difluoro-, 4-hydroxy-5-phenol-6,6′difluoro-, and 4-hydroxy-8-pheno-6,6′difluoro-, have the ability to increase the capacity for NO release in human endothelial cells following chronic administration. This invention provides hydroxylated nebivolol metabolites and compositions comprising nebivolol and/or at least one hydroxylated metabolite of nebivolol and/or at least one additional compound used to treat cardiovascular diseases or a pharmaceutically acceptable salt thereof. In addition, this invention provides methods of treating and/or preventing vascular diseases by administering at least one hydroxylated metabolite of nebivolol that is capable of releasing a therapeutically effective amount of nitric oxide to a targeted site affected by the vascular disease. Also, this invention is directed to the treatment and/or prevention of migraine headaches administering at least one hydroxylated metabolite of nebivolol. This invention may also be used in conjunction with or as a single treatment of metabolic syndrome disorders.

  羟基化奈必洛尔代谢物在急性给药后以浓度依赖性方式增加人内皮细胞制剂的一氧化氮释放。此外，羟基化奈必洛尔代谢物，包括但不限于4-羟基-6,6'-二氟代-、4-羟基-5-苯酚-6,6'-二氟代-和4-羟基-8-苯并-6,6'-二氟代-，在慢性给药后能够增加人内皮细胞的一氧化氮释放能力。本发明提供了羟基化奈必洛尔代谢物和包含奈必洛尔和/或至少一种羟基化奈必洛尔代谢物和/或至少一种用于治疗心血管疾病的附加化合物的组合物，以及可药用的盐。此外，本发明还提供了通过给药至少一种能够释放治疗有效量的一氧化氮到受血管疾病影响的靶向部位的羟基化奈必洛尔代谢物来治疗和/或预防血管疾病的方法。本发明还涉及通过给药至少一种羟基化奈必洛尔代谢物来治疗和/或预防偏头痛。本发明还可以与治疗代谢综合征障碍的其他治疗联合使用，或作为单一治疗。
• [EN] PHARMACOLOGICALLY ACTIVE IMIDAZO[4,5-C]PYRIDINES<br/>[FR] IMIDAZO[4,5-C]PYRIDINES A ACTIVITE PHARMACOLOGIQUE
  申请人：ALTANA PHARMA AG

  公开号：WO2005026164A1

  公开（公告）日：2005-03-24

  The invention relates to 6-substituted imidazo[4,5-c]pyridines of formula 1, in which X is O (oxygen) or NH and Y has either the meaning -CH2-AR or Y denotes the group gp (gp) wherein Z has the meaning -CHR8- or -CHR8-CHR9-. The compounds have gastric secretion inhibiting and excellent gastric and intestinal protective action properties.

  这项发明涉及式1中的6-取代咪唑并[4,5-c]吡啶，其中X为O（氧）或NH，Y具有含义-CH2-AR或Y表示该组gp（gp），其中Z具有含义-CHR8-或-CHR8-CHR9-。这些化合物具有抑制胃酸分泌和优异的胃肠保护作用特性。